About this medicine

Its depression and pain roles use the same active ingredient. A low dose prescribed for nerve pain does not imply that someone has depression.

This UK article concerns single-ingredient Brown & Burk tablets. It covers depression and separately licensed pain/headache uses, rather than assuming that every prescription is for depression. Elavil and Endep remain useful historical American search names, not verified current UK products.

What is this medicine used for?

Bedwetting licensing requires exclusion of physical causes and failure of other drug and non-drug treatments. It is not a general childhood-depression licence.

Preventive headache treatment aims to reduce future attacks, not to act as an immediate rescue medicine during each attack. Neuropathic pain arises from damage or disease affecting the nervous system. These treatment purposes should remain distinct when symptoms and benefit are reviewed.

Which warning signs need help?

Collapse, seizures, breathing difficulty or overdose need emergency assessment. New self-harm thoughts require urgent help. A spreading rash with fever or facial swelling can signal a severe drug reaction. Contact emergency services appropriate to your physical location.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

Amitriptyline overdose can cause dangerous heart-rhythm disturbances and seizures. Suspected excess dosing needs immediate medical assessment, even before obvious symptoms; this article does not provide an amount that can be assumed safe.

How do I take it safely?

Adult product reference: depression starts at 25 mg twice daily, with clinician-led increases up to 150 mg daily. Pain/headache prevention starts at 10–25 mg in the evening; the usual range is 25–75 mg daily. Older people need lower starting doses. This is not a self-adjustment schedule.

The 10 mg tablet's score helps swallowing; it is not validated to produce equal doses. Depression, pain and childhood enuresis schedules are not interchangeable. A swallowing problem should prompt discussion of a verified formulation, not crushing or dividing by assumption.

A UK oral liquid is also available in product information: the checked SyriMed solution contains 10 mg in 5 mL and covers the same listed adult and restricted enuresis indications. A liquid concentration is not a daily dose. Confirm the exact strength and prescribed volume instead of treating a teaspoon or another bottle's concentration as equivalent.

What side effects should I know about?

Sleepiness, dizziness, dry mouth, constipation, headache and difficulty passing urine are recognised. Persistent symptoms deserve review.

MHRA is adding the term post-SSRI sexual dysfunction (PSSD) to patient leaflets describing persistent sexual difficulties after stopping certain antidepressants, including this medicine. Their frequency and causes remain under study. Persistent symptoms deserve support; this does not mean everyone taking the medicine will experience them.

Postural hypotension means blood pressure falls on standing, causing dizziness or faintness. Older people can be particularly susceptible. Review the combined effects of sleepiness, visual changes and unsteadiness on driving and falls.

Who needs extra care with this medicine?

Recent heart attack, rhythm/conduction problems and severe liver disease are contraindications. Glaucoma, urinary retention, epilepsy and previous mania require discussion.

Can it affect my other medicines?

MAO inhibitors must not be combined with amitriptyline; switching requires prescribed waiting periods. Other serotonergic drugs, sedatives and medicines affecting heart rhythm or liver enzymes need checking.

Strong CYP2D6 inhibitors such as fluoxetine, paroxetine and bupropion can raise exposure and may require dose review or level monitoring. Combining anticholinergic medicines can compound bowel, bladder and heat-related problems. A pharmacist should review starts and stops, not only medicines taken simultaneously.

What check-ups will I need?

Review mood, falls, blood pressure and cardiac risk. The enuresis licence requires a pretreatment ECG and review before repeated courses.

Review whether the intended symptom has improved, not simply whether the person feels sleepy. Ask about bowel and bladder function, falls and cognition as well as mood. Monitoring is tailored to cardiac risk, co-prescribed medicines and the reason for treatment.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding require an individual risk–benefit decision. Newborn observation may be needed after late-pregnancy treatment. Older people are particularly vulnerable to postural dizziness.

A childhood bedwetting licence does not authorise childhood depression or pain treatment. Older people are more susceptible to anticholinergic effects and postural falls. The maternity or infant-feeding discussion should consider the specific condition being treated as well as maternal benefit and possible infant effects.

What if I miss a dose or want to stop?

Withdrawal can follow abrupt stopping; clinicians usually reduce treatment gradually. Do not double doses to replace a missed tablet.

How does it work?

Amitriptyline slows the return of serotonin and noradrenaline, chemical messengers, into the nerve cells that released them. This process is called reuptake, and slowing it leaves more messenger available between cells. The change affects communication involved in mood and pain, but does not establish that depression is simply a shortage of either chemical.

The UK product information also describes actions on ion channels, tiny openings that control the movement of electrically charged particles through nerve-cell membranes. These include channels involved in signalling in the brain and spinal cord, which can help explain pain-related effects beyond the antidepressant action. Amitriptyline’s effect on pain is therefore not simply a consequence of improving mood.

How does it affect my body?

Dryness, constipation and difficulty passing urine reflect effects beyond the brain. Drowsiness and dizziness can impair driving.

Sedation may appear before the antidepressant or pain benefit, which the label describes as usually emerging over two to four weeks. Anticholinergic effects involve acetylcholine signalling and help explain dryness, blurred vision, constipation and urinary difficulty.

How does my body process it?

Liver metabolism involves CYP2C19 and CYP2D6 and produces active nortriptyline. Genetic differences, interacting medicines and age affect exposure.

An active metabolite is a breakdown product that also has effects in the body. Here, nortriptyline contributes to exposure. Slower metabolism or inhibition of CYP2D6 can raise concentrations; a blood level may sometimes assist assessment but does not replace reviewing symptoms and adverse effects.

How do treatment options differ?

Nortriptyline is an active breakdown product but a separate prescribed medicine. Their doses and licensed uses are not interchangeable.

A closer look at the science

Muscarinic and histamine receptor effects contribute to its anticholinergic and sedating properties. Pharmacology alone cannot predict personal benefit.

The term tricyclic refers to a three-ring chemical structure. Chemical family, receptor effects and clinical use are related but different concepts: a similar-looking medicine cannot safely be substituted on the basis of its structure or tablet strength.

How was this medicine developed?

The checked 10 mg generic record lists first authorisation in July 2018. This dates that product, not the discovery of amitriptyline.

An older medicine can acquire new safety information. This UK record retains the October 2026 antidepressant communication rather than treating a long authorisation history as proof that warnings no longer change.

Sources and References

  1. Amitriptyline 10 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Amitriptyline 25 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Amitriptyline 50 mg — UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. Amitriptyline — patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  5. NHS: Amitriptyline side effects

    Scope: NHS.uk public information (England); not a statement of uniform services or funding across the four UK nations.

  6. NHS: About amitriptyline for depression

    Scope: NHS.uk public information (England); not a statement of uniform services or funding across the four UK nations.

  7. Antidepressants: use and safety

    Scope: United Kingdom.

  8. Amitriptyline hydrochloride 10 mg/5 mL oral solution — SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  9. Amitriptyline hydrochloride tablets prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology; Warnings; Precautions, Drug Interactions—Drugs Metabolized by P450 2D6; Adverse Reactions. This does not establish UK product authorisation or prescribing..

  10. What Is a Neurotransmitter? — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: How Neurotransmitters Work; Types of Neurotransmitters. This does not establish UK product authorisation or prescribing..

  11. Low blood pressure: MedlinePlus Medical Encyclopedia

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top